‘Scale Matters And Portfolio Matters’ – Biocon’s Erick On The US Biosimilars Market
CCO For Advanced Markets Also Foresees Wave Of Consolidation
Biocon Biologics chief commercial officer for advanced markets Matt Erick speaks to Generics Bulletin (Biocon) 
